Pacific Biosciences of California (PACB) Competitors $1.35 +0.09 (+7.14%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.36 +0.00 (+0.37%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PACB vs. TXG, HBIO, TMO, A, MTD, WAT, ILMN, TECH, CRL, and BIOShould you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), and Bio-Rad Laboratories (BIO). Pacific Biosciences of California vs. Its Competitors 10x Genomics Harvard Bioscience Thermo Fisher Scientific Agilent Technologies Mettler-Toledo International Waters Illumina Bio-Techne Charles River Laboratories International Bio-Rad Laboratories Pacific Biosciences of California (NASDAQ:PACB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Does the media favor PACB or TXG? In the previous week, 10x Genomics had 7 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 23 mentions for 10x Genomics and 16 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 0.88 beat Pacific Biosciences of California's score of 0.70 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 5 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 8 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, PACB or TXG? 10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacific Biosciences of California$154.01M2.63-$309.85M-$2.79-0.4810x Genomics$610.78M2.48-$182.63M-$1.30-9.45 Which has more risk & volatility, PACB or TXG? Pacific Biosciences of California has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Do institutionals and insiders have more ownership in PACB or TXG? 84.7% of 10x Genomics shares are owned by institutional investors. 2.5% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 9.4% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer PACB or TXG? Pacific Biosciences of California presently has a consensus price target of $1.88, suggesting a potential upside of 39.35%. 10x Genomics has a consensus price target of $13.50, suggesting a potential upside of 9.85%. Given Pacific Biosciences of California's higher possible upside, equities research analysts clearly believe Pacific Biosciences of California is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacific Biosciences of California 0 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.3810x Genomics 1 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.42 Is PACB or TXG more profitable? 10x Genomics has a net margin of -13.13% compared to Pacific Biosciences of California's net margin of -336.40%. 10x Genomics' return on equity of -13.15% beat Pacific Biosciences of California's return on equity.Company Net Margins Return on Equity Return on Assets Pacific Biosciences of California-336.40% -52.99% -15.60% 10x Genomics -13.13%-13.15%-10.20% Summary10x Genomics beats Pacific Biosciences of California on 12 of the 16 factors compared between the two stocks. Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PACB vs. The Competition Export to ExcelMetricPacific Biosciences of CaliforniaMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$405.11M$6.97B$5.53B$9.71BDividend YieldN/A1.34%4.60%4.12%P/E Ratio-0.5924.5230.0624.80Price / Sales2.6375.22427.94191.12Price / CashN/A20.9636.7758.47Price / Book0.735.638.195.60Net Income-$309.85M$178.18M$3.27B$266.27M7 Day Performance1.50%0.28%6.14%5.08%1 Month Performance-10.00%-5.41%0.07%0.61%1 Year Performance-15.09%5.71%36.43%22.83% Pacific Biosciences of California Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PACBPacific Biosciences of California2.5108 of 5 stars$1.35+7.1%$1.88+39.4%-15.1%$405.11M$154.01M-0.59730News CoverageEarnings ReportAnalyst UpgradeGap UpTXG10x Genomics3.7958 of 5 stars$14.64+3.8%$13.23-9.6%-39.8%$1.80B$610.78M-11.261,240Trending NewsEarnings ReportAnalyst ForecastGap UpHBIOHarvard Bioscience4.2571 of 5 stars$0.53-6.3%$3.00+466.9%-81.9%$23.40M$94.14M-0.40490Trending NewsUpcoming EarningsTMOThermo Fisher Scientific4.9925 of 5 stars$484.90+1.4%$593.00+22.3%-22.6%$183.04B$42.88B28.05125,000News CoveragePositive NewsAnalyst DowngradeInsider TradeAAgilent Technologies4.6987 of 5 stars$119.54-0.5%$139.77+16.9%-16.2%$33.96B$6.51B29.5217,900News CoveragePositive NewsMTDMettler-Toledo International3.7704 of 5 stars$1,259.15-0.4%$1,298.50+3.1%-10.2%$26.17B$3.87B31.4017,300Positive NewsWATWaters4.755 of 5 stars$302.51-0.1%$381.94+26.3%-15.6%$18.00B$2.96B27.457,600Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionILMNIllumina4.8901 of 5 stars$109.88+0.5%$125.89+14.6%-23.5%$17.39B$4.37B-18.109,030Positive NewsTECHBio-Techne4.9133 of 5 stars$58.55-0.4%$69.58+18.8%-29.7%$9.18B$1.21B71.403,100News CoverageEarnings ReportDividend AnnouncementAnalyst ForecastCRLCharles River Laboratories International4.6464 of 5 stars$179.10+1.2%$174.54-2.5%-25.8%$8.80B$4.05B-275.5420,100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionBIOBio-Rad Laboratories4.8602 of 5 stars$253.24-4.1%$324.25+28.0%-18.7%$6.89B$2.57B-3.327,700Positive News Related Companies and Tools Related Companies TXG Competitors HBIO Competitors TMO Competitors A Competitors MTD Competitors WAT Competitors ILMN Competitors TECH Competitors CRL Competitors BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PACB) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacific Biosciences of California With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
